Evidence map›Paper›PMID 36691120›Full record

ArticleBMJ open2022

Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial.

Molebogeng X Rangaka, Yohhei Hamada, Trinh Duong, Henry Bern, Joanna Calvert, Marie Francis, Amy Louise Clarke, Alex Ghanouni, Charlotte Layton, Vanessa Hack and 13 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 5 countries.

Molebogeng X RangakaInstitute for Global Health, University College London, London, UK l.rangaka@ucl.ac.uk.
Yohhei HamadaInstitute for Global Health, University College London, London, UK.ORCID 0000-0002-9845-4267
Trinh DuongMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.
Henry BernMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.
Joanna CalvertMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.
Marie FrancisInstitute for Global Health, University College London, London, UK.
Amy Louise ClarkeCentre for Behavioural Medicine, UCL School of Pharmacy, London, UK.
Alex GhanouniCentre for Behavioural Medicine, UCL School of Pharmacy, London, UK.
Charlotte LaytonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.
Vanessa HackInstitute for Global Health, University College London, London, UK.
Ellen Owen-PowellMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.
Julian SureyInstitute for Global Health, University College London, London, UK.
Karen SandersMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.
Helen L BoothNorth Central London Tuberculosis Service, Whittington Health NHS Trust and University College London Hospitals NHS Foundation Trust, London, UK.
Angela CrookMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.
Chris GriffithsWolfson Institute for Population Health Barts and the London School of Medicine and Dentistry, Queen Mary University, London, UK.ORCID 0000-0001-7935-8694
Robert HorneCentre for Behavioural Medicine, UCL School of Pharmacy, London, UK.
Heinke KunstBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.
Marc LipmanUCL Respiratory, Division of Medicine, University College, London, UK.ORCID 0000-0001-7501-4448
Mike MandelbaumTB Alert, Brighton, UK.
Peter J WhiteModelling and Economics Unit, National Infection Service, Public Health England, London, UK.
Dominik ZennerInstitute for Global Health, University College London, London, UK.
Ibrahim AbubakarInstitute for Global Health, University College London, London, UK.ORCID 0000-0002-0370-1430
MRC Clinical Trials Unit at UCL · GBUniversity College London · GBQueen Mary University of London · GBUniversity College Lahore · PKAll Africa Leprosy Tuberculosis and Rehabilitation Training Centre · ETInfectious Disease Research Institute · USPublic Health England · GBRoyal Free London NHS Foundation Trust · GBUniversity College London Hospitals NHS Foundation Trust · GB

Funding

Department of Health RP-PG-0217-20009Medical Research Council MC_UU_12023/27Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

introductionThe successful scale-up of a latent tuberculosis (TB) infection testing and treatment programme is essential to achieve TB elimination. However, poor adherence compromises its therapeutic effectiveness. Novel rifapentine-based regimens and treatment support based on behavioural science theory may improve treatment adherence and completion. METHODS AND ANALYSIS: A pragmatic multicentre, open-label, randomised controlled trial assessing the effect of novel short-course rifapentine-based regimens for TB prevention and additional theory-based treatment support on treatment adherence against standard-of-care. Participants aged between 16 and 65 who are eligible to start TB preventive therapy will be recruited in England. 920 participants will be randomised to one of six arms with allocation ratio of 5:5:6:6:6:6: daily isoniazid +rifampicin for 3 months (3HR), routine treatment support (control); 3HR, additional treatment support; weekly isoniazid +rifapentine for 3 months (3HP), routine treatment support; weekly 3HP, additional treatment support ; daily isoniazid +rifapentine for 1 month (1HP), routine treatment support; daily 1HP, additional treatment support. Additional treatment support comprises reminders using an electronic pillbox, a short animation, and leaflets based on the perceptions and practicalities approach. The primary outcome is adequate treatment adherence, defined as taking ≥90% of allocated doses within the pre-specified treatment period, measured by electronic pillboxes. Secondary outcomes include safety and TB incidence within 12 months. We will conduct process evaluation of the trial interventions and assess intervention acceptability and fidelity and mechanisms for effect and estimate the cost-effectiveness of novel regimens. The protocol was developed with patient and public involvement, which will continue throughout the trial. ETHICS AND DISSEMINATION: Ethics approval has been obtained from The National Health Service Health Research Authority (20/LO/1097). All participants will be required to provide written informed consent. We will share the results in peer-reviewed journals. TRIAL REGISTRATION NUMBER: EudraCT 2020-004444-29.

Indexed as

Latent TuberculosisRifampinAdolescentAdultAgedAntitubercular AgentsHumansIsoniazidMiddle AgedMulticenter Studies as TopicPragmatic Clinical Trials as TopicRandomized Controlled Trials as TopicState MedicineUnited KingdomYoung AdultAntitubercular AgentsIsoniazidRifampinrifapentineclinical trialspreventive medicinetuberculosis

Identifiers

PMID36691120
PMCPMC9454004
OpenAlexW4294770625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.